CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $230.44M, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
230.44MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.48xvs all stocks
52-Week Change
19.88%vs all stocks
Market Capitalization
230.44MUSDvs all stocks (USD)
Enterprise Value
97.71MUSDvs all stocks (USD)
Forward P/E
-2.49xvs Biotechnology peers
Price to Book (MRQ)
1.25xvs Biotechnology peers
Enterprise to EBITDA
-1.40xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-24.29%vs Biotechnology peers
Return on Equity (TTM)
-37.27%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-69.69MUSDvs all stocks (USD)
Net Income (TTM)
-63.31MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-62.99MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-39.34MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-64.55MUSDvs all stocks (USD)
Pre-tax Income
-57.44MUSDFY2025 · Dec 31, 2025Net Income
-57.44MUSDFY2025 · Dec 31, 2025EBIT
-64.55MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-64.24MUSDFY2025 · Dec 31, 2025Research & Development
42.63MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
21.92MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.33MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-57.44MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-53.84MUSDFY2025 · Dec 31, 2025Free Cash Flow
-53.94MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
50.40MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-57.44MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
362.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
3.83MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.08MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-873.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-802.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-94.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-204.63MUSDFY2025 · Dec 31, 2025Sale of Investments
65.23MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-139.49MUSDFY2025 · Dec 31, 2025Other Financing Charges
-799.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
80.17MUSDFY2025 · Dec 31, 2025Shares Outstanding
55.06MSharesUpdated Jul 19, 2026Float Shares
49.16MSharesUpdated Jul 19, 2026Shares Short
4.34MSharesUpdated Jul 19, 2026Short Ratio
5.62daysvs all stocks
Short % of Shares Outstanding
7.85%vs all stocks
% Held by Insiders
2.42%vs all stocks
% Held by Institutions
81.10%vs all stocks
Total Cash (MRQ)
135.79MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.42USDUpdated Jul 19, 2026Total Debt (MRQ)
3.06MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0169xvs Biotechnology peers
Current Ratio (MRQ)
15.69xvs Biotechnology peers
Book Value per Share (MRQ)
3.29USDUpdated Jul 19, 2026Total Assets
209.47MUSDvs all stocks (USD)
Total Current Assets
159.50MUSDFY2025 · Dec 31, 2025Total Liabilities
13.06MUSDFY2025 · Dec 31, 2025Total Non-current Assets
49.96MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.12MUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.94MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
49.66MUSDFY2025 · Dec 31, 2025Other Short-term Investments
105.90MUSDFY2025 · Dec 31, 2025Accounts Payable
3.47MUSDFY2025 · Dec 31, 2025Short-term Debt
1.24MUSDFY2025 · Dec 31, 2025Long-term Debt
2.12MUSDFY2025 · Dec 31, 2025Common Stock (Book)
54.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-302.42MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
196.41MUSDvs all stocks (USD)
52-Week Low
2.97USDUpdated Jul 19, 202652-Week High
7.82USDUpdated Jul 19, 202652-Week Change
19.88%vs all stocks
Beta
1.48xvs all stocks
50-Day MA
4.39USDUpdated Jul 19, 2026200-Day MA
5.33USDUpdated Jul 19, 2026Avg 10-Day Volume
567.42KSharesUpdated Jul 19, 2026Avg 30-Day Volume
738.12KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.36USDUpdated Jul 19, 2026Other Income / Expense
779.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.70
Altman Z-Score 8.4: safe zoneNotable
Altman Z-Score: 8.40
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $230.44M, lower than 95% of all stocks globallySignificant
Market cap (USD): 230,437,371Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Samyang Biopharmaceuticals Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Eubiologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Immunotech Biopharm Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shenqi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Acimmune SA
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Greenwich LifeSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anavex Life Sciences Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Intocell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Orchestra BioMed Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Nanjing Xinjiekou Department Store Co. Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Wave Life Sciences Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
SM Entertainment Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity